Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys aged 4 to 7 using a modified human dystrophin gene, the trial showed no significant progress, affecting Pfizer's quest for new treatments as it diversifies beyond its COVID-19 portfolio.
After the market close on Wednesday, Virgin Galactic announced that its board approved a 1-for-20 reverse stock split, effective after the market close on June 14. Virgin Galactic's common stock is expected to begin trading on a split-adjusted basis on June 17.
Signet Jewelers reported its first-quarter FY25 earnings, with sales decline of 9.5% year-on-year to $1.510 billion, marginally missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimate of $0.85.
Under the new agreement with the Central Florida Tourism Oversight District, Disney has pledged to invest a minimum of $8 billion in the resort over the next decade,
Honda Motorannounces the October launch of the N-VAN e, a versatile mini-electric vehicle designed for commercial use in Japan. With a reported price tag of ¥2.44 million ($15,550), the model supports a 245 km range per charge and features a unique design optimizing cargo space.
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have